TLDR AGX jumped ~10% in pre-market after Q4 EPS of $3.47 beat the $2.13 consensus by $1.34 Q4 revenue came in at $262.1M, up 12.7% year-over-year but slightly belowTLDR AGX jumped ~10% in pre-market after Q4 EPS of $3.47 beat the $2.13 consensus by $1.34 Q4 revenue came in at $262.1M, up 12.7% year-over-year but slightly below

Argan (AGX) Stock Jumps 10% After Record Q4 Earnings Beat

2026/03/27 21:46
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • AGX jumped ~10% in pre-market after Q4 EPS of $3.47 beat the $2.13 consensus by $1.34
  • Q4 revenue came in at $262.1M, up 12.7% year-over-year but slightly below the $271M estimate
  • Full-year FY26 EPS hit $9.74 vs $6.15 in FY25; gross margin expanded to 25% from 20.5%
  • Project backlog surged to $2.9B from $1.4B a year ago after $2.5B in new contracts
  • The company ended the year with $895M in cash and zero debt; FY27 revenue guidance of $415M–$440M beat the $385.68M consensus

Argan posted Q4 adjusted EPS of $3.47, well ahead of the $2.13 analyst estimate. That’s a beat of $1.34 per share — not the kind of number that goes unnoticed.


AGX Stock Card
Argan, Inc., AGX

Q4 revenue came in at $262.1 million, up 12.7% from $232.5 million in the same period last year. It did fall short of the $271 million estimate, but investors clearly focused on the profit story.

Gross profit margin expanded to 25% in Q4, up from 20.5% a year ago. Net income reached $49.2 million, compared to $31.4 million in the prior-year quarter.

For FY26, Argan reported revenue of $944.6 million, up 8.1% year-over-year. Full-year EPS came in at $9.74, up from $6.15 in FY25. EBITDA rose to $162.8 million from $113.5 million the prior year.

The standout number may be the backlog. It jumped to approximately $2.9 billion as of January 31, 2026, from $1.4 billion a year earlier. That growth came after the company added $2.5 billion in new contract value during FY26.

Watson pointed to strong demand from AI data center construction, electrification trends, and aging power infrastructure as drivers behind the new contract wins.

Balance Sheet and Dividend

Argan ended the year in a strong cash position. The company held $895 million in cash, cash equivalents, and investments, up from $525.1 million a year ago. Net liquidity stood at $421 million.

There is no debt on the balance sheet.

The company also raised its quarterly dividend to $0.50 per share in FY26, the third consecutive year of increases.

One key contributor to Q4 profitability was the early achievement of substantial completion at the Trumbull Energy Center — a milestone that helped lift gross margins for the quarter.

FY27 Outlook

Looking ahead, Argan issued FY27 revenue guidance of $415 million to $440 million. That range sits above the analyst consensus of $385.68 million.

Adjusted EBITDA for FY27 is expected in the range of $0 to $10 million. CFO Baugher noted it is still too early to give a clear view on FY27 gross margins.

The company expects to add new projects over the next 12 to 20 months.

AGX was trading near $450 in pre-market on March 27, up roughly 10% on the session. The stock had already been moving higher, up around 12.6% over the prior month and about 3.15% over the past week.

The post Argan (AGX) Stock Jumps 10% After Record Q4 Earnings Beat appeared first on CoinCentral.

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$0.51272
$0.51272$0.51272
-7.05%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags: